Analyst Price Targets — PROK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 4, 2024 7:50 am | Jason Gerberry | Bank of America Securities | $3.00 | $2.40 | TheFly | ProKidney price target lowered to $3 from $4 at BofA |
| September 3, 2024 4:49 pm | Justin Zelin | BTIG | $5.00 | $2.40 | StreetInsider | BTIG Reiterates Buy Rating on ProKidney Corp. (PROK) |
| June 10, 2024 12:53 pm | Kelly Shi | Jefferies | $6.00 | $3.02 | StreetInsider | ProKidney Corp. (PROK) PT Lowered to $6 at Jefferies |
| May 28, 2024 2:38 pm | Justin Zelin | BTIG | $6.00 | $3.71 | StreetInsider | BTIG Reiterates Buy Rating on ProKidney Corp. (PROK) |
| December 21, 2022 6:18 am | — | Jefferies | $15.00 | $7.30 | Benzinga | Jefferies Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $15 |
Latest News for PROK
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK's cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising 'going concern' doubts.
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PROK.
U.S. House Trading
No House trades found for PROK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.